TrialInternational journal of cancer2023

First-line nivolumab plus chemotherapy vs chemotherapy in patients with advanced gastric, gastroesophageal junction and esophageal adenocarcinoma: CheckMate 649 Chinese subgroup analysis.

Tianshu Liu et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.